Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $11.40 Average PT from Analysts

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been assigned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $11.40.

A number of equities research analysts recently commented on RVPH shares. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, January 21st. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 10th. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday, January 10th. Roth Mkm began coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, HC Wainwright dropped their price objective on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ RVPH opened at $1.18 on Friday. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.28. The company’s 50 day moving average price is $1.77 and its 200-day moving average price is $1.47. The company has a market capitalization of $39.46 million, a P/E ratio of -1.06 and a beta of -0.09.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of RVPH. Raymond James Financial Inc. purchased a new stake in Reviva Pharmaceuticals in the fourth quarter worth about $25,000. Cornerstone Select Advisors LLC purchased a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $32,000. Drive Wealth Management LLC bought a new stake in Reviva Pharmaceuticals during the 4th quarter worth approximately $36,000. XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals during the fourth quarter valued at approximately $45,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Reviva Pharmaceuticals by 848.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock worth $48,000 after purchasing an additional 23,953 shares during the period. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.